Sevacizumab

Drug Profile

Sevacizumab

Alternative Names: Anti-VEGF monoclonal antibody - Apexigen; APX-003; BD-0801; EP-10030; SIM-BD-0801; TK 001

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Epitomics
  • Developer Apexigen; Jiangsu T-mab BioPharma; Simcere Pharmaceutical Group
  • Class Antineoplastics; Eye disorder therapies; Monoclonal antibodies
  • Mechanism of Action Immunomodulators; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Colorectal cancer; Solid tumours
  • Phase I Wet age-related macular degeneration
  • No development reported Cancer

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
  • 01 Sep 2017 Jiangsu T-Mab Biopharma initiates enrolment in a phase I trial for Wet age-related macular degeneration (In adults, In the elderly) in China (Intravitreous, Injection) (NCT03021785)
  • 17 Jan 2017 Jiangsu T-Mab Biopharma plans a phase I trial for Wet age-related macular degeneration (In adults, In the elderly) in China (Intravitreous, Injection) (NCT03021785)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top